Abstract Details

Title Combination Antithrombotic Treatment for prevention of recurrent Ischemic Stroke in IntraCranial Atherosclerotic Disease: CATIS-ICAD

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P5 - Poster Session 5 (8:00 AM-9:00 AM)

Poster/Presentation
Number 4-005

Objective We aim to establish the safety and efficacy of low-dose rivaroxaban plus ASA in preventing recurrent strokes secondary to IntraCranial Atherosclerotic Disease (ICAD). The current pilot trial is designed to obtain the factual prerequisites essential for the design of a subsequent phase III trial.

Background ICAD is highly prevalent and a major cause of stroke. Patients with a recent ICAD related stroke are at a high risk for recurrent stroke (~5.5% at 30 days, 14.9% at 1 year, and 17.2% at 2 years) despite treatment with antiplatelet agents and aggressive management of vascular risk factors . There was overwhelming efficacy of the combination antithrombotic treatment (low-dose rivaroxaban - 2.5mg bid - plus ASA) compared with ASA alone for preventing vascular outcomes in patients with systemic atherosclerosis in the recent COMPASS trial. In 27,395 patients the combination therapy showed a 49% reduction of ischemic stroke (0.51 (0.38–0.68) <0.001). For those with prior ischemic stroke there was a 77% reduction of recurrent stroke with no increase in intracranial hemorrhage. With the low-dose rivaroxaban plus ASA combination there was a reduction of all ischemic strokes subtypes but the effect was significant for embolic strokes.

Design/Methods CATIS-ICAD is an open-label, blinded endpoint, randomized, controlled, investigator-initiated pilot study that will assess the recruitment feasibility and the safety of low-dose rivaroxaban plus ASA compared with ASA for stroke prevention in patients with ischemic stroke or high-risk Transient Ischemic Attack secondary to ICAD. Sample size of 100 patients was calculated based on convenience and will be recruited over 24 months.

Results "NA"

Conclusions CATIS-ICAD will assess the effectiveness of low-dose rivaroxaban plus ASA in patients with recent ischemic stroke / high-risk TIA secondary to ICAD, an area where a huge interest exists within the stroke community. The proposed study will advance our knowledge of ICAD related stroke risk factors and prevention.

Authors/Disclosures
Danielle De Sa Boasquevisque, MD (McMaster University) PRESENTER	No disclosure on file
Mike Sharma, MD (Population Health Research Institute)	Dr. Sharma has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bayer. Dr. Sharma has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Regeneron. Dr. Sharma has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anthos. Dr. Sharma has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. The institution of Dr. Sharma has received research support from Bayer.
Michael D. Hill, MD (University of Calgary)	Dr. Hill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Dr. Hill has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sun Pharma. Dr. Hill has received stock or an ownership interest from Circle Neurovascular.
	No disclosure on file
	No disclosure on file
Robert G. Hart, MD	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��